1. A Cross-Reactivity of Fenofibric Acid With MDMA DRI Assay.
- Author
-
Bugier, Sarah, Garcia-Hejl, Carine, Vest, Philippe, Plantamura, Julie, Chianea, Denis, and Renard, Christophe
- Subjects
- *
ECSTASY (Drug) , *GAS chromatography , *MASS spectrometry , *ARMY Physical Fitness Test , *DIAGNOSTIC errors , *DRUG design , *CLINICAL drug trials , *FENOFIBRATE , *FLUORESCENT antibody technique , *MOLECULAR structure , *MILITARY personnel , *STANDARDS , *THERAPEUTICS - Abstract
Background: Within the framework of routine fitness examinations, French Air Force military crew underwent urine testing for 3,4 methylenedioxymetamphetamine (MDMA [ecstasy]). The cross-reactivity of a dyslipidemic drug, fenofibrate, with an MDMA immunoassay was studied and confirmed on a large population sample.Methods: A 3-year retrospective study was performed on the MDMA DRI Ecstasy Assay on the Unicel DXC 600. In the event of positive test result, a confirmatory testing was carried out by gas chromatography/mass spectrometry (GC/MS) to establish the presence of MDMA. When analysis by GC/MS did not confirm the presence of MDMA, a false-positive result was suspected and the samples were analyzed by high-performance liquid chromatography-mass spectrometry to identify a potential interfering substance.Results: A total of 15,169 urine samples, from 7,803 patients, were tested for 3 years. Of the tested samples, 22 (0.15%) were positive by DRI Ecstasy Assay. None of them were positive by GC/MS. A cross-reactivity of fenofibrate's metabolite with MDMA using this assay was systematically found.Conclusion: Fenofibrate's interference with MDMA immunoassay was confirmed. Fenofibrate being widely prescribed, physicians had to be alerted that this treatment could lead to false-positive results. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF